Details of the Drug

General Information of Drug (ID: DMBGZI3)

Drug Name
Chlorpromazine
Synonyms
Aminasine; Aminazin; Aminazine; Ampliactil; Amplicitil; Amplictil; BC 135; Chlor-PZ; Chlor-Promanyl; Chlordelazine; Chlorderazin; Chloropromazine; Chlorpromados; Chlorpromanyl (discontinued); Chlorpromazin; Chlorpromazine (USP/INN); Chlorpromazine Tannate; Chlorpromazine [USAN:INN:BAN]; Chlorpromazinum; Chlorpromazinum [INN-Latin]; Clorpromazina; Clorpromazina [INN-Spanish]; Clorpromazina [Italian]; Contomin; Cromedazine; Elmarin; Esmind; Fenactil; Fenaktyl; Fraction AB; HL 5746; JHICC02042; Largactil; Largactil (TN); Largactil Liquid; Largactil Oral Drops; Largactilothiazine; Largactyl; Megaphen; Novo-Chlorpromazine; Novomazina; Phenactyl; Phenathyl; Phenothiazine hydrochloride; Plegomasine; Plegomazin; Prazilpromactil; Proma; Promactil; Promazil; Propaphen; Propaphenin; Prozil; Psychozine; SKF 2601-A; SKF 2601A; SKF-2601; Sanopron; Thorazine; Thorazine (TN); Thorazine Spansule; Thorazine Suppositories; Thorazine hydrochloride; Torazina; Wintermin; Z80
Indication
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Approved [1], [2]
Therapeutic Class
Antipsychotic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 318.9
Topological Polar Surface Area (xlogp) 5.2
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 16 mL/min/kg [4]
Elimination
0.5% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 11 hours [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 52.37222 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.056% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 10 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 400 mg/mL [3]
Chemical Identifiers
Formula
C17H19ClN2S
IUPAC Name
3-(2-chlorophenothiazin-10-yl)-N,N-dimethylpropan-1-amine
Canonical SMILES
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl
InChI
InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3
InChIKey
ZPEIMTDSQAKGNT-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2726
ChEBI ID
CHEBI:3647
CAS Number
34468-21-8
DrugBank ID
DB00477
TTD ID
D01ZII
VARIDT ID
DR00502
INTEDE ID
DR0308
ACDINA ID
D00124

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Antagonist [6], [7], [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [10]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [11]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [12]
Docosahexaenoic acid omega-hydroxylase (CYP4F11) DEIZLTN CP4FB_HUMAN Substrate [13]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Schizophrenia
ICD Disease Classification 6A20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D2 receptor (D2R) DTT DRD2 2.50E-02 -0.08 -0.49
P-glycoprotein 1 (ABCB1) DTP P-GP 9.39E-02 1.07E-01 2.80E-01
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 7.36E-01 1.62E-02 1.08E-01
Docosahexaenoic acid omega-hydroxylase (CYP4F11) DME CYP4F11 9.32E-03 1.82E-01 4.37E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 7.30E-01 -1.91E-02 -1.41E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Chlorpromazine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Quetiapine. Schizophrenia [6A20] [56]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Mesoridazine. Schizophrenia [6A20] [56]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Thioridazine. Schizophrenia [6A20] [57]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Aripiprazole. Schizophrenia [6A20] [58]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Iloperidone. Schizophrenia [6A20] [56]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Paliperidone. Schizophrenia [6A20] [56]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Haloperidol. Schizophrenia [6A20] [56]
Perphenazine DMA4MRX Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Perphenazine. Schizophrenia [6A20] [58]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Molindone. Schizophrenia [6A20] [58]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Thiothixene. Schizophrenia [6A20] [58]
Trifluoperazine DMKBYWI Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Trifluoperazine. Schizophrenia [6A20] [58]
Risperidone DMN6DXL Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Risperidone. Schizophrenia [6A20] [58]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Amisulpride. Schizophrenia [6A20] [59]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Asenapine. Schizophrenia [6A20] [56]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Pimozide. Schizophrenia [6A20] [60]
⏷ Show the Full List of 15 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Chlorpromazine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Ivosidenib. Acute myeloid leukaemia [2A60] [61]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Midostaurin. Acute myeloid leukaemia [2A60] [56]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Idarubicin. Acute myeloid leukaemia [2A60] [56]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Daunorubicin. Acute myeloid leukaemia [2A60] [56]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Arn-509. Acute myeloid leukaemia [2A60] [60]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Gilteritinib. Acute myeloid leukaemia [2A60] [62]
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Chlorpromazine and Oliceridine. Acute pain [MG31] [63]
Scopolamine DMOM8AL Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Scopolamine. Addictive disorder [6C50-6C5Z] [58]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [64]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [64]
Tripelennamine DMZBU15 Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [58]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Memantine. Alzheimer disease [8A20] [58]
Galantamine DMEO794 Moderate Antagonize the effect of Chlorpromazine when combined with Galantamine. Alzheimer disease [8A20] [65]
Rivastigmine DMG629M Moderate Antagonize the effect of Chlorpromazine when combined with Rivastigmine. Alzheimer disease [8A20] [65]
Donepezil DMIYG7Z Moderate Antagonize the effect of Chlorpromazine when combined with Donepezil. Alzheimer disease [8A20] [65]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Chlorpromazine and Metronidazole. Amoebiasis [1A36] [66]
Isosorbide dinitrate DMBI4JG Moderate Additive hypotensive effects by the combination of Chlorpromazine and Isosorbide dinitrate. Anal fissure/fistula [DB50] [67]
Trimethaphan DMHF4IQ Moderate Additive hypotensive effects by the combination of Chlorpromazine and Trimethaphan. Aneurysm/dissection [BD50] [68]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Ivabradine. Angina pectoris [BA40] [60]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Bepridil. Angina pectoris [BA40] [56]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Dronedarone. Angina pectoris [BA40] [56]
Amyl nitrite DMJKO05 Moderate Additive hypotensive effects by the combination of Chlorpromazine and Amyl nitrite. Angina pectoris [BA40] [67]
Nifedipine DMSVOZT Moderate Additive hypotensive effects by the combination of Chlorpromazine and Nifedipine. Angina pectoris [BA40] [67]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [69]
Hydroxyzine DMF8Y74 Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [58]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Cilostazol. Arterial occlusive disease [BD40] [56]
Voriconazole DMAOL2S Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Voriconazole. Aspergillosis [1F20] [56]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Posaconazole. Aspergillosis [1F20] [56]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Levalbuterol. Asthma [CA23] [70]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Terbutaline. Asthma [CA23] [71]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Pirbuterol. Asthma [CA23] [71]
Ephedrine DMMV0KW Moderate Antagonize the effect of Chlorpromazine when combined with Ephedrine. Asthma [CA23] [72]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Salbutamol. Asthma [CA23] [70]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Formoterol. Asthma [CA23] [71]
Lisdexamfetamine DM6W8V5 Moderate Antagonize the effect of Chlorpromazine when combined with Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [72]
Desipramine DMT2FDC Moderate Increased plasma concentrations of Chlorpromazine and Desipramine due to competitive inhibition of the same metabolic pathway. Attention deficit hyperactivity disorder [6A05] [73]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Ofloxacin. Bacterial infection [1A00-1C4Z] [74]
Ciprofloxacin XR DM2NLS9 Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [56]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Clarithromycin. Bacterial infection [1A00-1C4Z] [56]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Chlorpromazine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [56]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [74]
Linezolid DMGFPU2 Moderate Additive hypotensive effects by the combination of Chlorpromazine and Linezolid. Bacterial infection [1A00-1C4Z] [75]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [74]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Norfloxacin. Bacterial infection [1A00-1C4Z] [74]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Levofloxacin. Bacterial infection [1A00-1C4Z] [74]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Lomefloxacin. Bacterial infection [1A00-1C4Z] [56]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Telithromycin. Bacterial infection [1A00-1C4Z] [56]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Retigabine. Behcet disease [4A62] [56]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Cariprazine. Bipolar disorder [6A60] [58]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Chlorpromazine and Loperamide. Bowel habit change [ME05] [76]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Eribulin. Breast cancer [2C60-2C6Y] [56]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Lapatinib. Breast cancer [2C60-2C6Y] [56]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Tamoxifen. Breast cancer [2C60-2C6Y] [56]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Toremifene. Breast cancer [2C60-2C6Y] [56]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Sotalol. Cardiac arrhythmia [BC9Z] [56]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [77]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [78]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [71]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [70]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Tiotropium. Chronic obstructive pulmonary disease [CA22] [78]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Salmeterol. Chronic obstructive pulmonary disease [CA22] [71]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [78]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [71]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [71]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Chlorpromazine and Dihydrocodeine. Chronic pain [MG30] [79]
Oxaliplatin DMQNWRD Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Oxaliplatin. Colorectal cancer [2B91] [56]
Isoproterenol DMK7MEY Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Isoproterenol. Conduction disorder [BC63] [70]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Halothane. Corneal disease [9A76-9A78] [56]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Propofol. Corneal disease [9A76-9A78] [80]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Sevoflurane. Corneal disease [9A76-9A78] [56]
Alfentanil DMVO0UB Major Additive CNS depression effects by the combination of Chlorpromazine and Alfentanil. Corneal disease [9A76-9A78] [63]
Remifentanil DMZTXCH Major Additive CNS depression effects by the combination of Chlorpromazine and Remifentanil. Corneal disease [9A76-9A78] [63]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Probucol. Coronary atherosclerosis [BA80] [56]
Dextromethorphan DMUDJZM Moderate Decreased metabolism of Chlorpromazine caused by Dextromethorphan mediated inhibition of CYP450 enzyme. Cough [MD12] [66]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Clofazimine. Crohn disease [DD70] [81]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Mifepristone. Cushing syndrome [5A70] [56]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Pasireotide. Cushing syndrome [5A70] [56]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Chlorpromazine caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [66]
Cyclandelate DMO0R76 Moderate Additive hypotensive effects by the combination of Chlorpromazine and Cyclandelate. Dementia [6D80-6D8Z] [67]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Sertraline. Depression [6A70-6A7Z] [56]
Trimipramine DM1SC8M Moderate Increased plasma concentrations of Chlorpromazine and Trimipramine due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [73]
Cyclobenzaprine DM1YBRM Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Cyclobenzaprine. Depression [6A70-6A7Z] [58]
Nortriptyline DM4KDYJ Moderate Increased plasma concentrations of Chlorpromazine and Nortriptyline due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [73]
Paroxetine DM5PVQE Moderate Decreased metabolism of Chlorpromazine caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [82]
Selegiline DM6034S Moderate Additive CNS depression effects by the combination of Chlorpromazine and Selegiline. Depression [6A70-6A7Z] [75]
Isocarboxazid DMAF1NB Moderate Additive CNS depression effects by the combination of Chlorpromazine and Isocarboxazid. Depression [6A70-6A7Z] [75]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Escitalopram. Depression [6A70-6A7Z] [56]
Tranylcypromine DMGB5RE Moderate Additive hypotensive effects by the combination of Chlorpromazine and Tranylcypromine. Depression [6A70-6A7Z] [75]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Chlorpromazine and OPC-34712. Depression [6A70-6A7Z] [58]
Phenelzine DMHIDUE Moderate Additive hypotensive effects by the combination of Chlorpromazine and Phenelzine. Depression [6A70-6A7Z] [75]
Clomipramine DMINRKW Moderate Increased plasma concentrations of Chlorpromazine and Clomipramine due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [73]
Trazodone DMK1GBJ Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Trazodone. Depression [6A70-6A7Z] [83]
Amoxapine DMKITQE Moderate Increased plasma concentrations of Chlorpromazine and Amoxapine due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [73]
Doxepin DMPI98T Moderate Increased plasma concentrations of Chlorpromazine and Doxepin due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [73]
Maprotiline DMPWB7T Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Maprotiline. Depression [6A70-6A7Z] [58]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Chlorpromazine and Esketamine. Depression [6A70-6A7Z] [66]
Nitroglycerin DMQ2491 Moderate Additive hypotensive effects by the combination of Chlorpromazine and Nitroglycerin. Diabetic foot ulcer [BD54] [67]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Mepenzolate. Digestive system disease [DE2Z] [58]
Tetrabenazine DMYWQ0O Major Additive antidopaminergic effects by the combination of Chlorpromazine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [84]
Meclizine DMS7T13 Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Meclizine. Dizziness and giddiness [MB48] [58]
Deutetrabenazine DMUPFLI Major Additive antidopaminergic effects by the combination of Chlorpromazine and Deutetrabenazine. Dystonic disorder [8A02] [85]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Ingrezza. Dystonic disorder [8A02] [86]
Zonisamide DM0DTF7 Major Additive CNS depression effects by the combination of Chlorpromazine and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [87]
Diphenhydramine DMKQTBA Moderate Antagonize the effect of Chlorpromazine when combined with Diphenhydramine. Episodic vestibular syndrome [AB31] [88]
Guanabenz DM5QWEL Moderate Additive hypotensive effects by the combination of Chlorpromazine and Guanabenz. Essential hypertension [BA00] [67]
Ethacrynic acid DM60QMR Moderate Additive hypotensive effects by the combination of Chlorpromazine and Ethacrynic acid. Essential hypertension [BA00] [68]
Phenoxybenzamine DM8KSQH Moderate Additive hypotensive effects by the combination of Chlorpromazine and Phenoxybenzamine. Essential hypertension [BA00] [67]
Nicardipine DMCDYW7 Moderate Additive hypotensive effects by the combination of Chlorpromazine and Nicardipine. Essential hypertension [BA00] [67]
Mecamylamine DMGQFYB Moderate Additive hypotensive effects by the combination of Chlorpromazine and Mecamylamine. Essential hypertension [BA00] [67]
Benzthiazide DMQWZ0H Moderate Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Benzthiazide. Essential hypertension [BA00] [66]
Nadolol DMW6GVL Moderate Additive hypotensive effects by the combination of Chlorpromazine and Nadolol. Essential hypertension [BA00] [67]
Mirabegron DMS1GYT Moderate Decreased metabolism of Chlorpromazine caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [89]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Tolterodine. Functional bladder disorder [GC50] [58]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Chlorpromazine caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [90]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Pentamidine. Fungal infection [1F29-1F2F] [56]
Terbinafine DMI6HUW Moderate Decreased metabolism of Chlorpromazine caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [91]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Ketoconazole. Fungal infection [1F29-1F2F] [56]
Amphotericin B DMTAJQE Moderate Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Amphotericin B. Fungal infection [1F29-1F2F] [66]
Phentolamine DMXYJOB Moderate Additive hypotensive effects by the combination of Chlorpromazine and Phentolamine. Gangrene [MC85] [67]
Propantheline DM2EN6G Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Propantheline. Gastric ulcer [DA60] [58]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Cisapride. Gastro-oesophageal reflux disease [DA22] [56]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [56]
Acetazolamide DM1AF5U Moderate Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Acetazolamide. Glaucoma [9C61] [66]
Isoflurophate DMBSK7X Moderate Antagonize the effect of Chlorpromazine when combined with Isoflurophate. Glaucoma [9C61] [92]
Carteolol DMFMDOB Moderate Additive hypotensive effects by the combination of Chlorpromazine and Carteolol. Glaucoma [9C61] [67]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Chlorpromazine and Brimonidine. Glaucoma [9C61] [93]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Chlorpromazine when combined with Pilocarpine. Glaucoma [9C61] [92]
Eplerenone DMF0NQR Moderate Additive hypotensive effects by the combination of Chlorpromazine and Eplerenone. Heart failure [BD10-BD1Z] [67]
Carvedilol DMHTEAO Moderate Increased plasma concentrations of Chlorpromazine and Carvedilol due to competitive inhibition of the same metabolic pathway. Heart failure [BD10-BD1Z] [94]
Chlorothiazide DMLHESP Moderate Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Chlorothiazide. Heart failure [BD10-BD1Z] [66]
Furosemide DMMQ8ZG Moderate Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Furosemide. Heart failure [BD10-BD1Z] [66]
Amiloride DMRTSGP Moderate Additive hypotensive effects by the combination of Chlorpromazine and Amiloride. Heart failure [BD10-BD1Z] [67]
Bumetanide DMRV7H0 Moderate Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Bumetanide. Heart failure [BD10-BD1Z] [66]
Hydroflumethiazide DMVPUQI Moderate Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Hydroflumethiazide. Heart failure [BD10-BD1Z] [66]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Chlorpromazine and Procarbazine. Hodgkin lymphoma [2B30] [75]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [95]
Cobicistat DM6L4H2 Moderate Decreased clearance of Chlorpromazine due to the transporter inhibition by Cobicistat. Human immunodeficiency virus disease [1C60-1C62] [96]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [97]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [98]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [56]
Abacavir DMMN36E Minor Increased plasma concentrations of Chlorpromazine and Abacavir due to competitive inhibition of the same metabolic pathway. Human immunodeficiency virus disease [1C60-1C62] [99]
Ritonavir DMU764S Moderate Decreased metabolism of Chlorpromazine caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [100]
Isosorbide mononitrate DMYLMU0 Moderate Additive hypotensive effects by the combination of Chlorpromazine and Isosorbide mononitrate. Hydrocephalus [8D64] [67]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Chlorpromazine caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [66]
Eprosartan DM07K2I Moderate Additive hypotensive effects by the combination of Chlorpromazine and Eprosartan. Hypertension [BA00-BA04] [67]
Acebutolol DM0TI4U Moderate Additive hypotensive effects by the combination of Chlorpromazine and Acebutolol. Hypertension [BA00-BA04] [67]
Moexipril DM26E4B Moderate Additive hypotensive effects by the combination of Chlorpromazine and Moexipril. Hypertension [BA00-BA04] [67]
Bisoprolol DM3UZ95 Moderate Additive hypotensive effects by the combination of Chlorpromazine and Bisoprolol. Hypertension [BA00-BA04] [67]
Captopril DM458UM Moderate Additive hypotensive effects by the combination of Chlorpromazine and Captopril. Hypertension [BA00-BA04] [67]
Penbutolol DM4ES8F Moderate Additive hypotensive effects by the combination of Chlorpromazine and Penbutolol. Hypertension [BA00-BA04] [67]
Trandolapril DM4L6EU Moderate Additive hypotensive effects by the combination of Chlorpromazine and Trandolapril. Hypertension [BA00-BA04] [67]
Methyldopa DM5I621 Moderate Additive hypotensive effects by the combination of Chlorpromazine and Methyldopa. Hypertension [BA00-BA04] [67]
Losartan DM72JXH Moderate Additive hypotensive effects by the combination of Chlorpromazine and Losartan. Hypertension [BA00-BA04] [67]
Nebivolol DM7F1PA Moderate Additive hypotensive effects by the combination of Chlorpromazine and Nebivolol. Hypertension [BA00-BA04] [67]
Fosinopril DM9NJ52 Moderate Additive hypotensive effects by the combination of Chlorpromazine and Fosinopril. Hypertension [BA00-BA04] [67]
Doxazosin DM9PLRH Moderate Additive hypotensive effects by the combination of Chlorpromazine and Doxazosin. Hypertension [BA00-BA04] [67]
TAK-491 DMCF6SX Moderate Additive hypotensive effects by the combination of Chlorpromazine and TAK-491. Hypertension [BA00-BA04] [67]
Pindolol DMD2NV7 Moderate Increased plasma concentrations of Chlorpromazine and Pindolol due to competitive inhibition of the same metabolic pathway. Hypertension [BA00-BA04] [94]
Fenoldopam DMFAOKP Moderate Additive hypotensive effects by the combination of Chlorpromazine and Fenoldopam. Hypertension [BA00-BA04] [67]
Indapamide DMGN1PW Moderate Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Indapamide. Hypertension [BA00-BA04] [66]
Benazepril DMH1M9B Moderate Additive hypotensive effects by the combination of Chlorpromazine and Benazepril. Hypertension [BA00-BA04] [67]
Trichlormethiazide DMHAQCO Moderate Additive hypotensive effects by the combination of Chlorpromazine and Trichlormethiazide. Hypertension [BA00-BA04] [67]
Labetalol DMK8U72 Moderate Additive hypotensive effects by the combination of Chlorpromazine and Labetalol. Hypertension [BA00-BA04] [67]
Enalapril DMNFUZR Moderate Additive hypotensive effects by the combination of Chlorpromazine and Enalapril. Hypertension [BA00-BA04] [67]
Perindopril DMOPZDT Moderate Additive hypotensive effects by the combination of Chlorpromazine and Perindopril. Hypertension [BA00-BA04] [67]
Felodipine DMOSW35 Moderate Additive hypotensive effects by the combination of Chlorpromazine and Felodipine. Hypertension [BA00-BA04] [67]
Quinapril DMR8H31 Moderate Additive hypotensive effects by the combination of Chlorpromazine and Quinapril. Hypertension [BA00-BA04] [67]
Deserpidine DMRH7CV Moderate Additive hypotensive effects by the combination of Chlorpromazine and Deserpidine. Hypertension [BA00-BA04] [67]
Telmisartan DMS3GX2 Moderate Additive hypotensive effects by the combination of Chlorpromazine and Telmisartan. Hypertension [BA00-BA04] [67]
Irbesartan DMTP1DC Moderate Additive hypotensive effects by the combination of Chlorpromazine and Irbesartan. Hypertension [BA00-BA04] [67]
Hydralazine DMU8JGH Moderate Additive hypotensive effects by the combination of Chlorpromazine and Hydralazine. Hypertension [BA00-BA04] [67]
Lisinopril DMUOK4C Moderate Additive hypotensive effects by the combination of Chlorpromazine and Lisinopril. Hypertension [BA00-BA04] [67]
Hydrochlorothiazide DMUSZHD Moderate Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Hydrochlorothiazide. Hypertension [BA00-BA04] [66]
Clevidipine butyrate DMW4M97 Moderate Additive hypotensive effects by the combination of Chlorpromazine and Clevidipine butyrate. Hypertension [BA00-BA04] [67]
Fludrocortisone DMUDIR8 Moderate Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Fludrocortisone. Hypo-osmolality/hyponatraemia [5C72] [66]
Givosiran DM5PFIJ Moderate Decreased metabolism of Chlorpromazine caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [66]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Amantadine. Influenza [1E30-1E32] [101]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Chlorpromazine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [102]
Propiomazine DMKY8V1 Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Propiomazine. Insomnia [7A00-7A0Z] [58]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Chlorpromazine and ITI-007. Insomnia [7A00-7A0Z] [58]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Polyethylene glycol. Irritable bowel syndrome [DD91] [56]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Phenolphthalein. Irritable bowel syndrome [DD91] [56]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Clidinium. Irritable bowel syndrome [DD91] [58]
Dicyclomine DMZSDGX Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Dicyclomine. Irritable bowel syndrome [DD91] [58]
Physostigmine DM2N0TO Moderate Antagonize the effect of Chlorpromazine when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [65]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Chlorpromazine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [60]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Crizotinib. Lung cancer [2C25] [103]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Chlorpromazine and Porfimer Sodium. Lung cancer [2C25] [104]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Ceritinib. Lung cancer [2C25] [56]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Chlorpromazine caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [105]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Osimertinib. Lung cancer [2C25] [106]
Capmatinib DMYCXKL Moderate Decreased metabolism of Chlorpromazine caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [66]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Selpercatinib. Lung cancer [2C25] [60]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Lumefantrine. Malaria [1F40-1F45] [66]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Halofantrine. Malaria [1F40-1F45] [107]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Chloroquine. Malaria [1F40-1F45] [108]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Hydroxychloroquine. Malaria [1F40-1F45] [108]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Primaquine. Malaria [1F40-1F45] [56]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [60]
IPI-145 DMWA24P Moderate Decreased metabolism of Chlorpromazine caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [109]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [110]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Vemurafenib. Melanoma [2C30] [56]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and LGX818. Melanoma [2C30] [111]
Ethinyl estradiol DMODJ40 Moderate Decreased clearance of Chlorpromazine due to the transporter inhibition by Ethinyl estradiol. Menopausal disorder [GA30] [112]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Chlorpromazine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [113]
Propranolol DM79NTF Moderate Increased plasma concentrations of Chlorpromazine and Propranolol due to competitive inhibition of the same metabolic pathway. Migraine [8A80] [94]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Chlorpromazine and Lasmiditan. Migraine [8A80] [114]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Chlorpromazine and Flibanserin. Mood disorder [6A60-6E23] [115]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Panobinostat. Multiple myeloma [2A83] [116]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Chlorpromazine and Thalidomide. Multiple myeloma [2A83] [117]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Siponimod. Multiple sclerosis [8A40] [66]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Fingolimod. Multiple sclerosis [8A40] [56]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Ozanimod. Multiple sclerosis [8A40] [118]
Methoxsalen DME8FZ9 Moderate Increased risk of photosensitivity reactions by the combination of Chlorpromazine and Methoxsalen. Mycosis fungoides [2B01] [66]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Romidepsin. Mycosis fungoides [2B01] [56]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Chlorpromazine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [60]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Nilotinib. Myeloproliferative neoplasm [2A20] [56]
Imatinib DM7RJXL Moderate Decreased metabolism of Chlorpromazine caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [119]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Dasatinib. Myeloproliferative neoplasm [2A20] [120]
Dextroamphetamine DMMIHVP Moderate Antagonize the effect of Chlorpromazine when combined with Dextroamphetamine. Narcolepsy [7A20] [72]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Phenindamine. Nasopharyngitis [CA00] [58]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Dimenhydrinate. Nausea/vomiting [MD90] [58]
Promethazine DM6I5GR Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Promethazine. Nausea/vomiting [MD90] [58]
Rolapitant DM8XP26 Moderate Decreased metabolism of Chlorpromazine caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [121]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Cyclizine. Nausea/vomiting [MD90] [58]
Metoclopramide DMFA5MY Major Additive antidopaminergic effects by the combination of Chlorpromazine and Metoclopramide. Nausea/vomiting [MD90] [122]
Granisetron DMIUW25 Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Granisetron. Nausea/vomiting [MD90] [56]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Dolasetron. Nausea/vomiting [MD90] [56]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Ondansetron. Nausea/vomiting [MD90] [56]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Chlorpromazine and Bupropion. Nicotine use disorder [6C4A] [56]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Entrectinib. Non-small cell lung cancer [2C25] [66]
Phendimetrazine DM6TS1N Moderate Antagonize the effect of Chlorpromazine when combined with Phendimetrazine. Obesity [5B80-5B81] [72]
Amfepramone DM9YSNQ Moderate Antagonize the effect of Chlorpromazine when combined with Amfepramone. Obesity [5B80-5B81] [72]
Lorcaserin DMG6OYJ Moderate Increased risk of hyperprolactinemic effects by the combination of Chlorpromazine and Lorcaserin. Obesity [5B80-5B81] [123]
Benzphetamine DMIJATC Moderate Antagonize the effect of Chlorpromazine when combined with Benzphetamine. Obesity [5B80-5B81] [72]
Mazindol DMZ36RN Moderate Antagonize the effect of Chlorpromazine when combined with Mazindol. Obesity [5B80-5B81] [72]
Metolazone DMB39LO Moderate Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Metolazone. Oedema [MG29] [66]
Polythiazide DMCH80F Moderate Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Polythiazide. Oedema [MG29] [66]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Levomethadyl Acetate. Opioid use disorder [6C43] [60]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Lofexidine. Opioid use disorder [6C43] [56]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Chlorpromazine and Apraclonidine. Optic nerve disorder [9C40] [93]
Rofecoxib DM3P5DA Moderate Decreased metabolism of Chlorpromazine caused by Rofecoxib mediated inhibition of CYP450 enzyme. Osteoarthritis [FA00-FA05] [66]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Rucaparib. Ovarian cancer [2C73] [56]
Pentazocine DM1XBHS Major Additive CNS depression effects by the combination of Chlorpromazine and Pentazocine. Pain [MG30-MG3Z] [63]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Chlorpromazine and Dextropropoxyphene. Pain [MG30-MG3Z] [124]
Butorphanol DM5KYPJ Major Additive CNS depression effects by the combination of Chlorpromazine and Butorphanol. Pain [MG30-MG3Z] [63]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Chlorpromazine and Oxymorphone. Pain [MG30-MG3Z] [63]
Levorphanol DMGS80V Major Additive CNS depression effects by the combination of Chlorpromazine and Levorphanol. Pain [MG30-MG3Z] [63]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Chlorpromazine and Dezocine. Pain [MG30-MG3Z] [63]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Flavoxate. Pain [MG30-MG3Z] [58]
Nalbuphine DMOSQGU Major Additive CNS depression effects by the combination of Chlorpromazine and Nalbuphine. Pain [MG30-MG3Z] [63]
Methamphetamine DMPM4SK Moderate Antagonize the effect of Chlorpromazine when combined with Methamphetamine. Pain [MG30-MG3Z] [125]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Chlorpromazine and Buprenorphine. Pain [MG30-MG3Z] [126]
Hydrocodone DMQ2JO5 Major Additive CNS depression effects by the combination of Chlorpromazine and Hydrocodone. Pain [MG30-MG3Z] [63]
Oxycodone DMXLKHV Major Additive CNS depression effects by the combination of Chlorpromazine and Oxycodone. Pain [MG30-MG3Z] [63]
Thiabendazole DM7YCK3 Moderate Decreased metabolism of Chlorpromazine caused by Thiabendazole mediated inhibition of CYP450 enzyme. Parasitic worm infestation [1F90] [66]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Triclabendazole. Parasitic worm infestation [1F90] [56]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Chlorpromazine and Safinamide. Parkinsonism [8A00] [75]
Pergolide DM14MAE Moderate Antagonize the effect of Chlorpromazine when combined with Pergolide. Parkinsonism [8A00] [127]
Opicapone DM1BKA6 Moderate Antagonize the effect of Chlorpromazine when combined with Opicapone. Parkinsonism [8A00] [127]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Chlorpromazine and Rasagiline. Parkinsonism [8A00] [75]
Biperiden DME78OA Moderate Antagonize the effect of Chlorpromazine when combined with Biperiden. Parkinsonism [8A00] [88]
Entacapone DMLBVKQ Moderate Antagonize the effect of Chlorpromazine when combined with Entacapone. Parkinsonism [8A00] [127]
Levodopa DMN3E57 Moderate Antagonize the effect of Chlorpromazine when combined with Levodopa. Parkinsonism [8A00] [127]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Pimavanserin. Parkinsonism [8A00] [128]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Orphenadrine. Parkinsonism [8A00] [58]
Apomorphine DMX38HQ Moderate Antagonize the effect of Chlorpromazine when combined with Apomorphine. Parkinsonism [8A00] [129]
Abametapir DM2RX0I Moderate Decreased metabolism of Chlorpromazine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [130]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Methylscopolamine. Peptic ulcer [DA61] [58]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Famotidine. Peptic ulcer [DA61] [66]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Macimorelin. Pituitary gland disorder [5A60-5A61] [131]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Lefamulin. Pneumonia [CA40] [132]
Hydrocortisone DMGEMB7 Moderate Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Hydrocortisone. Postoperative inflammation [1A00-CA43] [66]
Ritodrine DM4V6RL Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Ritodrine. Preterm labour/delivery [JB00] [71]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Degarelix. Prostate cancer [2C82] [60]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Chlorpromazine caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [133]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Nilutamide. Prostate cancer [2C82] [60]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Enzalutamide. Prostate cancer [2C82] [60]
Flutamide DMK0O7U Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Flutamide. Prostate cancer [2C82] [60]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Relugolix. Prostate cancer [2C82] [60]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Bicalutamide. Prostate cancer [2C82] [60]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Chlorpromazine and Terazosin. Prostate hyperplasia [GA90] [67]
Tamsulosin DM5QF9V Moderate Additive hypotensive effects by the combination of Chlorpromazine and Tamsulosin. Prostate hyperplasia [GA90] [67]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Chlorpromazine and Silodosin. Prostate hyperplasia [GA90] [67]
Levomepromazine DMIKFEL Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Levomepromazine. Psychotic disorder [6A20-6A25] [58]
Fluphenazine DMIT8LX Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Fluphenazine. Psychotic disorder [6A20-6A25] [58]
Triflupromazine DMKFQJP Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Triflupromazine. Psychotic disorder [6A20-6A25] [58]
Tolazoline DMI40NL Moderate Additive hypotensive effects by the combination of Chlorpromazine and Tolazoline. Pulmonary hypertension [BB01] [67]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [134]
Neupro DMHEAB1 Moderate Antagonize the effect of Chlorpromazine when combined with Neupro. Restless legs syndrome [7A80] [127]
Celecoxib DM6LOQU Moderate Decreased metabolism of Chlorpromazine caused by Celecoxib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [135]
Fentanyl DM8WAHT Major Additive CNS depression effects by the combination of Chlorpromazine and Fentanyl. Sensation disturbance [MB40] [63]
Sufentanil DMU7YEL Major Additive CNS depression effects by the combination of Chlorpromazine and Sufentanil. Sensation disturbance [MB40] [63]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Vardenafil. Sexual dysfunction [HA00-HA01] [56]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Chlorpromazine and LEE011. Solid tumour/cancer [2A00-2F9Z] [56]
Cisplatin DMRHGI9 Moderate Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Cisplatin. Solid tumour/cancer [2A00-2F9Z] [66]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [56]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [60]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [56]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Pitolisant. Somnolence [MG42] [56]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [56]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Adenosine. Supraventricular tachyarrhythmia [BC81] [56]
Fostamatinib DM6AUHV Moderate Decreased clearance of Chlorpromazine due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [136]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Lenvatinib. Thyroid cancer [2D10] [56]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Cabozantinib. Thyroid cancer [2D10] [60]
Papaverine DMCA9QP Moderate Additive hypotensive effects by the combination of Chlorpromazine and Papaverine. Tonus and reflex abnormality [MB47] [67]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Chlorpromazine and Tizanidine. Tonus and reflex abnormality [MB47] [137]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Tacrolimus. Transplant rejection [NE84] [56]
Atropine DMEN6X7 Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Atropine. Unspecific substance harmful effect [NE6Z] [58]
Astemizole DM2HN6Q Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Astemizole. Vasomotor/allergic rhinitis [CA08] [56]
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [58]
Methdilazine DMAUHQX Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Methdilazine. Vasomotor/allergic rhinitis [CA08] [58]
Carbinoxamine DMCT31R Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [58]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [58]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [58]
Azatadine DMZ80SB Moderate Additive anticholinergic effects by the combination of Chlorpromazine and Azatadine. Vasomotor/allergic rhinitis [CA08] [58]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Procainamide. Ventricular tachyarrhythmia [BC71] [56]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Propafenone. Ventricular tachyarrhythmia [BC71] [56]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Chlorpromazine and Flecainide. Ventricular tachyarrhythmia [BC71] [56]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Chlorpromazine and Amiodarone. Ventricular tachyarrhythmia [BC71] [56]
⏷ Show the Full List of 320 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
D&C red no. 30 E00456 3000709 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
methylparaben E00149 7456 Antimicrobial preservative
Propyl 4-hydroxybenzoate E00141 7175 Antimicrobial preservative
Quinoline yellow WS E00309 24671 Colorant
Sodium benzoate E00432 517055 Antimicrobial preservative; lubricant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Allyl sucrose E00604 129637651 Other agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium sulfate anhydrous E00303 24497 Desiccant; Diluent
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 17 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Chlorpromazine 100 mg tablet 100 mg Oral Tablet Oral
Chlorpromazine 25 mg tablet 25 mg Oral Tablet Oral
Chlorpromazine 50 mg tablet 50 mg Oral Tablet Oral
Chlorpromazine 10 mg tablet 10 mg Oral Tablet Oral
Chlorpromazine 200 mg tablet 200 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 83).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 080439.
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
7 Basolateral amygdala D1- and D2-dopaminergic system promotes the formation of long-term potentiation in the dentate gyrus of anesthetized rats. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):552-6.
8 Behavioral and neurochemical methods in research on new psychotropics. Ann Pharm Fr. 1998;56(2):54-9.
9 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
10 Effect of classic and atypical neuroleptics on cytochrome P450 3A (CYP3A) in rat liver. Pharmacol Rep. 2012;64(6):1411-8.
11 Use of antidepressant drugs in schizophrenic patients with depression. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9.
12 Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Aug 15;31(6):1297-302.
13 Expression and characterization of human cytochrome P450 4F11: putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):295-304.
14 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
15 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
16 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
17 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
18 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
19 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
20 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
21 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
22 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
23 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
24 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
25 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
26 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
27 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
28 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
29 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
30 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
31 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
32 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
33 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
34 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
35 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
36 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
37 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
38 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
39 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
40 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
41 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
42 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
43 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
44 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
45 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
46 The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
47 Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
48 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
49 Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
50 Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
51 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
52 Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
53 [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
54 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
55 Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. Psychiatry Clin Neurosci. 2009 Jun;63(3):322-8.
56 Canadian Pharmacists Association.
57 Bluhm RE, Wilkinson GR, Shelton R, Branch RA "Genetically determined drug-metabolizing activity and desipramine- associated cardiotoxicity: a case report." Clin Pharmacol Ther 53 (1993): 89-95. [PMID: 8422746]
58 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
59 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
60 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
61 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
62 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
63 Cerner Multum, Inc. "Canadian Product Information.".
64 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
65 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
66 Cerner Multum, Inc. "Australian Product Information.".
67 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
68 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
69 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
70 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
71 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
72 Achor MB, Extein I "Diet aids, mania, and affective illness" Am J Psychiatry 138 (1981): 392. [PMID: 7468847]
73 Bock JL, Nelson JC, Gray S, Jatlow PI "Desipramine hydroxylation: variability and effect of antipsychotic drugs." Clin Pharmacol Ther 33 (1983): 322-8. [PMID: 6130865]
74 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
75 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
76 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
77 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
78 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
79 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
80 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
81 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
82 Nicholson SD "Extra pyramidal side effects associated with paroxetine." West Engl Med J 107 (1992): 90-1. [PMID: 1308691]
83 Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]
84 Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
85 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
86 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
87 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
88 Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm 2 (1983): 174-8. [PMID: 6883947]
89 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
90 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
91 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
92 Multum Information Services, Inc. Expert Review Panel.
93 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
94 Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9. [PMID: 7663034]
95 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
96 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
97 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
98 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
99 Product Information. Ziagen (abacavir). Glaxo Wellcome, Research Triangle Pk, NC.
100 Product Information. Norvir (ritonavir). Abbott Pharmaceutical, Abbott Park, IL.
101 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
102 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
103 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
104 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
105 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
106 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
107 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
108 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
109 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
110 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
111 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
112 Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8. [PMID: 8162660]
113 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
114 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
115 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
116 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
117 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
118 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
119 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
120 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
121 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
122 Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
123 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
124 Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
125 Lake CR "Manic psychosis after coffee and phenylpropanolamine." Biol Psychiatry 30 (1991): 401-4. [PMID: 1912131]
126 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
127 Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
128 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
129 Product Information. Apokyn (apomorphine). Mylan Pharmaceuticals Inc, Morgantown, WV.
130 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
131 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
132 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
133 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
134 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
135 Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
136 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
137 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.